Croatia's national medicines regulatory authority, specialising in pharmacovigilance systems and EU-wide medicine identification data standards.
HALMED is Croatia's national medicines and medical devices regulatory authority — the Croatian equivalent of the European Medicines Agency at the national level. Their core work involves authorizing medicinal products for the Croatian market, running national pharmacovigilance (drug safety) systems, and maintaining the national medicine database. In EU research projects, they contribute their position as an operational national competent authority: real regulatory workflows, access to national medicine registries, and the ability to test and validate standards in a live regulatory environment. Their H2020 involvement focused specifically on interoperable medicine identification and digital adverse drug reaction reporting — both areas where national regulators are irreplaceable partners.
Participated in WEB-RADR 2 (mobile/web ADR reporting platform) and UNICOM (which includes pharmacovigilance data standardisation as a keyword), reflecting HALMED's core regulatory function of drug safety monitoring.
UNICOM (2019-2024) is dedicated to implementing ISO IDMP standards for univocal medicine identification across EU member states, a task that directly involves national regulatory databases HALMED maintains.
UNICOM keywords include CEF (Connecting Europe Facility), eHealth Network, and Cross-border eHealth, indicating HALMED's role in connecting national medicine data into EU-wide interoperable infrastructure.
UNICOM explicitly lists 'drug database' and 'standardisation' as keywords, reflecting HALMED's contribution of its national medicinal product registry as a real-world implementation testbed.
HALMED's early H2020 engagement (WEB-RADR 2, 2018-2020) focused on the citizen-facing and clinical side of pharmacovigilance — specifically web and mobile tools for collecting adverse drug reaction reports. Their subsequent project (UNICOM, 2019-2024) shifted the emphasis upstream toward the regulatory and data infrastructure layer: standardising how medicines are identified across EU systems using IDMP, connecting national databases via the Connecting Europe Facility, and aligning with EMA's master data strategy. The direction is clear: from reporting tools toward foundational data interoperability infrastructure that underpins all digital health exchanges involving medicinal products.
HALMED is moving toward a role as a national node in EU-wide medicine data infrastructure — making them a relevant partner for any project that needs regulatory data interoperability, IDMP implementation, or cross-border medicine safety systems.
HALMED participates exclusively as a consortium partner, never as coordinator — consistent with the role of a national public authority that brings regulatory legitimacy and operational data access rather than research management capacity. Both their projects involved large, multi-country consortia (UNICOM had over 20 partners across EU member states), where HALMED's value is its status as an active national competent authority rather than its research output. Working with them means getting a real regulatory environment for testing and validation, and a direct connection to Croatian national medicine registration workflows.
Despite only two projects, HALMED has built connections with 48 unique partners across 20 countries — unusually broad for such a small portfolio, reflecting the large multi-national consortia typical of IMI and eHealth infrastructure projects. Their network skews toward other EU national regulatory agencies, pharmaceutical industry partners, and health IT providers.
HALMED is one of 27 EU national competent authorities for medicines — an irreplaceable category of partner for any project that needs real regulatory validation, access to national medicine registries, or cross-border eHealth compliance testing. Unlike universities or research institutes, they bring operational authority: decisions HALMED makes about medicine registration and pharmacovigilance are legally binding in Croatia and feed into EMA's European systems. For consortium builders targeting EU medicine data infrastructure, IDMP rollout, or pharmacovigilance platform development, a national regulator on board is often a requirement, not a nice-to-have.
